Account
Insider Insights
04.07.2024
Hemgenix becomes the first treatment to enter NHS ...

New ground-breaking gene therapy for haemophilia B enters NHS England's Innovative Medicines Fund, o...

Read more
Insider Insights
03.07.2024
The transformation of healthcare through personali...

The rise of personalised medicine is revolutionizing healthcare, prompting a re-evaluation of tradit...

Read more
Insider Insights
30.05.2024
NICE and NHS England unveil plan to facilitate qui...

NHS and NICE propose faster adoption of MedTech, streamlining funding and market access for innovati...

Read more
Insider Insights
23.04.2024
NICE Approves CAR-Therapy for NHS

NICE recommends Kymriah® for routine NHS use, offering immense benefits for those with resistant B-...

Read more
Insider Insights
16.02.2024
Biosimilar Switching in Germany from March 15, 202...

New biosimilar switching regulations prioritise cost-effective options and discount agreements, imp...

Read more
Articles
24.01.2024
What are the 5 Pricing & Market Access trends...

Our experts provide an overview of the five key trends that could shape the pricing and market acces...

Read more
Insider Insights
24.07.2023
Johnson & Johnson sue the US government

J&J sues US government, alleging infringement on First Amendment rights and unfair drug pricing unde...

Read more
Insider Insights
12.06.2023
CMS sets inflation penalties on 43 drugs

In a move towards curbing rising drug prices, the Inflation Reduction Act (IRA) provision will impos...

Read more
News
17.05.2023
PMA Insights: Week 20 SPECIAL EDITION – ISPO...

We summarise ISPOR Annual 2023 including plenary sessions on artificial intelligence, real-world evi...

Read more
Publications
09.05.2023
ISPOR US 2023: Plenary Session 1 – Global Fo...

Our experts provide a detailed summary of Plenary Session 1 at ISPOR Annual 2023 on global affordabi...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.